SCHEMBL30793987

SCHEMBL30793987

CNc1nn2c(c1Cl)CNCCC2

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30793973 0.83
SCHEMBL30793843 0.81
SCHEMBL30793892 0.81
SCHEMBL30793253 0.79
SCHEMBL30793352 0.79 HTR2A (0.32)
SCHEMBL25339293 0.76 CXCR4 (0.34) CXCR4
SCHEMBL31057579 0.74 GLP1R (0.32) CXCR4
SCHEMBL26686886 0.73 CXCR4 (0.38) CXCR4
SCHEMBL31057594 0.71 CXCR4 (0.36) CXCR4
SCHEMBL30793737 0.71 PDE4A (0.39) CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 WO disclosed